Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Enanta Pharmaceutica
(NQ:
ENTA
)
13.30
+0.21 (+1.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Enanta Pharmaceutica
< Previous
1
2
3
4
Next >
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
August 05, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
May 29, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
May 07, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) Near the Top of Equities by Percentage Gain on 11/21
November 21, 2023
Via
Investor Brand Network
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
May 06, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
April 30, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
April 29, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
April 17, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference
March 06, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET
February 07, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023
January 31, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference
November 22, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET
November 20, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023
November 13, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline
October 13, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
September 17, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023
September 07, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate in Investor Conferences in September
August 31, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
August 07, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023
July 31, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
June 20, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023
June 07, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference
May 31, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate in Two Investor Conferences in May
May 09, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
May 08, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
May 08, 2023
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.